$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023 ; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in
Paper published in the November 2022 issue of Podiatry Management ( Robert J. Snyder , DPM, Cyaandi Dove, DPM, and Vickie Driver , DPM, MS) YAVNE, Israel , Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time YAVNE, Israel , Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities YAVNE, Israel , Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic
EscharEx’s promising results from the completed Phase 2 trials were highlighted YAVNE, Israel , Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today
Gross Proceeds of $30.5 Million Raised YAVNE, Israel , Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously
YAVNE, Israel , Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities
Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns YAVNE, Israel , Sept. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presence at the recently
Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 , 202 3 for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all B egins T oday at 8:30 AM Eastern Time YAVNE, Israel , Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
